Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 20 de 48 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:17 de noviembre. [Ref.ID 100990]
2. Cita con resumen
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Balckwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobssen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48. [Ref.ID 100961]
3.Tiene citas relacionadas Cita con resumen
Park JW, Liu MC, Yee D, Yau C, van't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, for the I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl J Med 2016;375:11-22. [Ref.ID 100626]
4. Cita con resumen
Anónimo. Palbociclib (Ibrance) for metastatic breast cancer. Med Lett Drugs Ther 2015;57:115-6. [Ref.ID 99465]
5. Cita con resumen
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, for the CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34. [Ref.ID 98817]
6. Cita con resumen
Yeo B, Turner NC, Jones A. Medical management of breast cancer. BMJ 2014;348:g3608. [Ref.ID 98044]
7.Tiene citas relacionadas Cita con resumen
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, Jackisch C, de Azambuja E, Procter M, Suter TM, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne C-H, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J, for the Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013;382:1021-8. [Ref.ID 96181]
8.Tiene citas relacionadas
Joensuu H. Duration of adjuvant trastuzumab: shorter beats longer. Lancet 2013;382:1010-1. [Ref.ID 96180]
9.Enlace a cita original
Anónimo. FDA approves new treatment for late-stage breast cancer. U.S. Food and Drug Administration 2013:22 de febrero. [Ref.ID 94711]
10.Tiene citas relacionadas
Teicher BA, Doroshow JH. The promise of antibody - Drug conjugates. N Engl J Med 2012;367:1847-8. [Ref.ID 94026]
11.Tiene citas relacionadas Cita con resumen
Verma S, Miles D, Gianni L, Krop IE, Weislau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, for the EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91. [Ref.ID 94023]
12.Tiene citas relacionadas Cita con resumen
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang T-W, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, on behalf of the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40. [Ref.ID 92390]
13.Tiene citas relacionadas
Gnant M, Steger GG. Dual inhibition of HER2 in breast cancer treatment. Lancet 2012;379:596-8. [Ref.ID 92386]
14.Tiene citas relacionadas Cita con resumen
Montero AJ, Vogel C. Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med 2012;366:374-5. [Ref.ID 92280]
15.Tiene citas relacionadas Cita con resumen
Bear HD, Tang G, Rastogi P, Geyer Jr CE, Robidoux A, Atkins JN, Baez-Díaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366:310-20. [Ref.ID 92279]
16.Tiene citas relacionadas Cita con resumen
von Minckwitz G, Eldtmann H, Rezai M, Fasching PA, Tesch H, Egemann H, Schrader I, Kittel K, Hausch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer J-U, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekjudova V, Untch M, for the German Breast Group and the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366:299-309. [Ref.ID 92278]
17.Tiene citas relacionadas
Gradishar WJ. HER2 therapy - An abundance of riches. N Engl J Med 2012;366:176-8. [Ref.ID 92211]
18.Tiene citas relacionadas Cita con resumen
Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Plenkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, for the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19. [Ref.ID 92209]
19.Tiene citas relacionadas
Hayes DF. Steady progress against HER2-positive breast cancer. N Engl J Med 2011;365:1336-8. [Ref.ID 91536]
20.Tiene citas relacionadas Cita con resumen
Slamon D, Eiermann W, Robert N, Pienkow T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M-C, Sauter G, von Minchwitz G, Visco F, Bee V, Buyse M, Bendahmana B, Tabah-Fisch I, Lindsay M-A, Riva A, Crown J, for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83. [Ref.ID 91532]
Seleccionar todas
 
 1 a 20 de 48 siguiente >>